**Preauthorization is required for Medicare Advantage members; for all other products this protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.**

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered.

### Populations

<table>
<thead>
<tr>
<th>Individuals:</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>• With loss of hand and upper-extremity function due to spinal cord injury or stroke</td>
<td>Interventions of interest are: • Functional neuromuscular electrical stimulation</td>
<td>Comparators of interest are: • Standard of care</td>
<td>Relevant outcomes include: • Functional outcomes • Quality of life</td>
</tr>
<tr>
<td>Individuals:</td>
<td>Interventions of interest are: • Functional neuromuscular electrical stimulation</td>
<td>Comparators of interest are: • Standard of care • Ankle-foot orthosis</td>
<td>Relevant outcomes include: • Functional outcomes • Quality of life</td>
</tr>
<tr>
<td>• With chronic footdrop</td>
<td>Interventions of interest are: • Functional neuromuscular electrical stimulation</td>
<td>Comparators of interest are: • Standard of care</td>
<td>Relevant outcomes include: • Functional outcomes • Quality of life</td>
</tr>
<tr>
<td>Individuals:</td>
<td>Interventions of interest are: • Functional neuromuscular electrical stimulation</td>
<td>Comparators of interest are: • Standard of care</td>
<td>Relevant outcomes include: • Functional outcomes • Quality of life</td>
</tr>
<tr>
<td>• With spinal cord injury at segments T4 to T12</td>
<td>Interventions of interest are: • Functional neuromuscular electrical stimulation</td>
<td>Comparators of interest are: • Standard of care</td>
<td>Relevant outcomes include: • Functional outcomes • Quality of life</td>
</tr>
</tbody>
</table>

### DESCRIPTION

Functional neuromuscular electrical stimulation (NMES) involves the use of an orthotic device with microprocessor-controlled electrical muscular stimulation. These devices are being developed to restore function to patients with damaged or destroyed nerve pathways (e.g., spinal cord injury [SCI], stroke, multiple sclerosis, cerebral palsy).

### SUMMARY OF EVIDENCE

For individuals who have loss of hand and upper-extremity function due to SCI or stroke who receive functional NMES, the evidence includes case series. Relevant outcomes are functional outcomes and quality of life. Evidence on functional NMES for the upper limb in patients with SCI or stroke includes a few small case series. Interpretation of the evidence is limited by the low number of patients studied and lack of data demonstrating the utility of NMES outside the investigational setting. It is uncertain whether NMES can restore some upper-
extremity function or improve the quality of life. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have chronic footdrop who receive functional NMES, the evidence includes randomized controlled trials and a systematic review. Relevant outcomes are functional outcomes and quality of life. For chronic poststroke footdrop, two large randomized trials have shown improved patient satisfaction with NMES; however, in objective measures (e.g., walking), no significant difference has been observed between NMES and a standard ankle-foot orthosis. A small randomized trial examining neuromuscular stimulation for footdrop in patients with multiple sclerosis revealed a clinically significant reduction in falls; the trial also revealed an improvement in patient satisfaction with the neuromuscular stimulation (as opposed to an exercise program). However, in the area of walking speed, the trial failed to demonstrate a clinically significant benefit to the neuromuscular stimulation over an exercise class. Studies in a larger number of patients are needed to provide greater certainty about the generalizability of this health outcome. The literature on NMES for footdrop in children with cerebral palsy includes a systematic review of small studies that feature within-subject designs; additional study in a larger number of subjects is needed. Overall, there is insufficient evidence for some indications, and a lack of improvement in objective measures for others. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have SCI at segments T4 to T12 who receive functional NMES, the evidence includes case series. Relevant outcomes are functional outcomes and quality of life. No controlled trials were identified on functional NMES for standing and walking in patients with SCI. However, case series are considered adequate for this condition, because there is no chance for unaided ambulation in this population with SCI at this level. Some studies have reported improvements in intermediate outcomes, but improvements in health outcomes (e.g., ability to perform activities of daily living, quality of life) have not been demonstrated. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

Neuromuscular stimulation is considered investigational as a technique to restore function following nerve damage or nerve injury. This includes its use in the following situations:

- To provide upper extremity function in patients with nerve damage (e.g., spinal cord injury or poststroke); or
- To improve ambulation in patients with foot drop caused by congenital disorders (e.g., cerebral palsy) or nerve damage (e.g., poststroke or in those with multiple sclerosis); or
- As a technique to provide ambulation in patients with spinal cord injury.

POLICY GUIDELINES

This policy does not refer to commercially available exercycles that use electrical muscle stimulation technology as a means of physical therapy and exercise for patients with spinal cord injury. These exercycles are sometimes called functional neuromuscular exercisers. The goals for using these devices may be to promote cardiovascular conditioning, prevent muscle atrophy, and/or maintain bone mass. The patient’s legs are wrapped in fabric strips that contain electrodes to stimulate the muscles, thus permitting the patient to pedal.

MEDICARE ADVANTAGE

For Medicare Advantage NMES/FES is medically necessary for spinal cord injury (SCI) patients for walking, who
have completed a training program which consists of at least 32 physical therapy sessions with the device over a period of three months. (See Medicare Advantage Policy Guidelines)

NMES/FES for walking is **medically necessary** in SCI patients with all of the following characteristics:

1. Persons with intact lower motor units (L1 and below) (both muscle and peripheral nerve);
2. Persons with muscle and joint stability for weight bearing at upper and lower extremities that can demonstrate balance and control to maintain an upright support posture independently;
3. Persons that demonstrate brisk muscle contraction to NMES and have sensory perception of electrical stimulation sufficient for muscle contraction;
4. Persons that possess high motivation, commitment and cognitive ability to use such devices for walking;
5. Persons that can transfer independently and can demonstrate independent standing tolerance for at least three minutes;
6. Persons that can demonstrate hand and finger function to manipulate controls;
7. Persons with at least six-month post recovery spinal cord injury and restorative surgery;
8. Persons without hip and knee degenerative disease and no history of long bone fracture secondary to osteoporosis; and
9. Persons who have demonstrated a willingness to use the device long-term.

NMES/FES for walking is **not medically necessary** in SCI patient with any of the following:

1. Persons with cardiac pacemakers;
2. Severe scoliosis or severe osteoporosis;
3. Skin disease or cancer at area of stimulation;
4. Irreversible contracture; or
5. Autonomic dysreflexia.

It might be **medically necessary** for certain patients receiving NMES treatment to use, as an alternative to conventional electrodes, adhesive tapes and lead wires, a form-fitting conductive garment (i.e., a garment with conductive fibers which are separated from the patients’ skin by layers of fabric).

A form-fitting conductive garment (and medically necessary related supplies) may be considered **medically necessary** only when:

1. It has received permission or approval for marketing by the Food and Drug Administration;
2. It has been prescribed by a physician for use in delivering covered NMES treatment; and
3. One of the medical indications outlined below is met:
   - The patient cannot manage without the conductive garment because there is such a large area or so many sites to be stimulated and the stimulation would have to be delivered so frequently that it is not feasible to use conventional electrodes, adhesive tapes and lead wires;
   - The patient has a documented medical condition such as skin problems that preclude the application of conventional electrodes, adhesive tapes and lead wires;
   - The patient has a medical need for rehabilitation strengthening (pursuant to a written plan of rehabilitation) following an injury where the nerve supply to the muscle is intact.
MEDICARE ADVANTAGE POLICY GUIDELINES

The trial period of physical therapy will enable the physician treating the patient for his or her spinal cord injury to properly evaluate the person’s ability to use these devices frequently and for the long term. Physical therapy necessary to perform this training must be directly performed by the physical therapist as part of a one-on-one training program.

The only settings where therapists with the sufficient skills to provide these services are employed are inpatient hospitals; outpatient hospitals; comprehensive outpatient rehabilitation facilities; and outpatient rehabilitation facilities.

The goal of physical therapy must be to train SCI patients on the use of neuromuscular electrical stimulation/functional electrical stimulation (NMES/FES) devices to achieve walking, not to reverse or retard muscle atrophy.

BACKGROUND

FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION

Functional neuromuscular electrical stimulation (NMES) is an approach to rehabilitation that applies low-level electrical current to stimulate functional movements in muscles affected by nerve damage. It focuses on the restoration of useful movements, like standing, stepping, pedaling for exercise, reaching, or grasping.

Functional NMES devices consist of an orthotic and a microprocessor-based electronic stimulator with one or more channels for delivery of individual pulses through surface or implanted electrodes connected to the neuromuscular system. Microprocessor programs activate the channels sequentially or in unison to stimulate peripheral nerves and trigger muscle contractions to produce functionally useful movements that allow patients to sit, stand, walk, and grasp. Functional neuromuscular stimulators are closed-loop systems that provide feedback information on muscle force and joint position, thus allowing constant modification of stimulation parameters, which are required for complex activities (e.g., walking). These systems are contrasted with open-loop systems, which are used for simple tasks (e.g., muscle strengthening alone); healthy individuals with intact neural control benefit the most from this technology.

Applications

Upper-Extremity Function After Spinal Cord Injury and Stroke

One application of functional NMES is to restore upper-extremity functions such as grasp-release, forearm pronation, and elbow extension in patients with stroke, or C5 and C6 tetraplegia (quadriplegia). NeuroControl Corp. developed the Freehand System, an implantable upper-extremity neuroprosthesis, to improve the ability to grasp, hold, and release objects for patients with tetraplegia due to C5 or C6 spinal cord injury (SCI). NeuroControl is no longer in business, but NMES centers in the United States and United Kingdom provide maintenance for implanted devices. The NESS H200 (previously known as the Handmaster NMS I system) is an upper-extremity device that uses a forearm splint and surface electrodes. The device, controlled by a user-activated button, is intended to provide hand function (fine finger grasping, larger palmar grasping) for patients with C5 tetraplegia or stroke.

Footdrop

Other functional NMES devices have been developed to provide functional NMES for patients with footdrop. Footdrop is weakness of the foot and ankle that causes reduced dorsiflexion and difficulty with ambulation. It can have various causes such as cerebral palsy, stroke, or multiple sclerosis. Functional electrical stimulation of the peroneal nerve has been suggested for these patients as an aid in raising the toes during the swing phase of ambulation. With these devices, a pressure sensor detects heel-off and initial contact during walking. A signal is then sent to the stimulation cuff, initiating or pausing the stimulation of the peroneal nerve, which activates the
foot dorsiflexors. Examples of such devices used for treatment of footdrop are the Innovative Neurotronics’ WalkAide, Bioness’s radiofrequency controlled NESS L300, Otto Bock’s MyGait, and the OFDS (Odstock Foot Drop Stimulator). An implantable peroneal nerve stimulator system (ActiGait®) is being developed in Europe.

**Ambulation After SCI**

Another application of functional electrical stimulation is to provide patients with SCI the ability to stand and walk. Generally, only SCI patients with lesions from T4 to T12 are considered candidates for ambulation systems. Lesions at T1 to T3 are associated with poor trunk stability, while lumbar lesions imply lower-extremity nerve damage. Using percutaneous stimulation, the device delivers trains of electrical pulses to trigger action potentials at selected nerves at the quadriceps (for knee extension), the common peroneal nerve (for hip flexion), and the paraspinals and gluteals (for trunk stability). Patients use a walker or elbow-support crutches for further support. The electric impulses are controlled by a computer microchip attached to the patient’s belt, which synchronizes and distributes the signals. In addition, there is a finger-controlled switch that permits patient activation of the stepping.

Other devices include a reciprocating gait orthosis with electrical stimulation. The orthosis used is a cumbersome hip-knee-ankle-foot device linked together with a cable at the hip joint. The use of this device may be limited by the difficulties in donning and doffing the device.

**Other Applications**

Other devices, such as the ReGrasp (Rehabtronics), are used for rehabilitation rather than home use. Neuromuscular stimulation is also proposed for motor restoration in hemiplegia and treatment of secondary dysfunction (e.g., muscle atrophy, alterations in cardiovascular function and bone density) associated with damage to motor nerve pathways. These applications are not addressed herein.

**REGULATORY STATUS**

In 1997, the Freehand® System was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process. The implantable Freehand® System is no longer marketed in the United States. The Handmaster NMS I system (now named NESS H200®) was originally cleared for marketing by FDA through the 510(k) process for maintaining or improving range of motion, reducing muscle spasm, preventing or retarding muscle atrophy, providing muscle re-education, and improving circulation (K022776); in 2001, its 510(k) marketing clearance was expanded to include provision of hand active range of motion and function for patients with C5 tetraplegia. FDA product code: GZC.

The WalkAide® System (Innovative Neurotronics, Gainesville, FL; formerly NeuroMotion) was first cleared for marketing by FDA through the 510(k) process in the 1990s (K052329); the current version of the WalkAide® device received 510(k) marketing clearance in 2005. The ODFS® (Odstock Dropped Foot Stimulator; Odstock Medical, Salisbury, U.K.) received 510(k) marketing clearance in 2005 (K050991). The NESS L300® (Bioness, Valencia, CA) was cleared for marketing by FDA through the 510(k) process in 2006. In 2015, the MyGait® Stimulation System (Otto Bock HealthCare, Duderstadt, Germany) received 510(k) marketing clearance (K141812). FDA summaries of the devices state that they are intended for patients with footdrop and assist with ankle dorsiflexion during the swing phase of gait. FDA product code: GZI.

To date, the Parastep® Ambulation System (Sigmedics, Northfield, IL) is the only noninvasive functional walking neuromuscular stimulation device to receive premarket approval from FDA. The Parastep® device is approved to “enable appropriately selected skeletally mature spinal cord injured patients (level C6-T12) to stand and attain limited ambulation and/or take steps, with assistance if required, following a prescribed period of physical therapy training in conjunction with rehabilitation management of spinal cord injury.” FDA product code: MKD.
RELATED PROTOCOL
Myoelectric Prosthetic and Orthotic Components for the Upper Limb

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.

REFERENCES
We are not responsible for the continuing viability of web site addresses that may be listed in any references below.


